TREATMENT READING

Childhood Acute Myeloid Leukemia, part 2

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

87 sections

For patients · Treatment Option Overview / Seven types of standard treatment may be used for childhood AML and other myeloid malignancies.

Targeted therapy

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Types of targeted therapy include the following:

Sources: Targeted therapy

Tyrosine kinase inhibitor therapy: This treatment blocks the enzyme, tyrosine kinase, that causes stem cells to become more white blood cells (blasts) than the body needs. Tyrosine kinase inhibitors may be used with chemotherapy drugs as adjuvant therapy (treatment given after the initial treatment, to lower the risk that the cancer will come back).

Sources: Tyrosine kinase inhibitor · enzyme · white blood cells · blasts · adjuvant therapy

Imatinib, dasatinib, and nilotinib are used to treat childhood chronic myelogenous leukemia.

Sources: Imatinib · dasatinib · nilotinib

Sorafenib, midostaurin, and gilteritinib, which target a mutated (changed) form of a gene called FLT3, are being studied to treat childhood AML.

Sources: Sorafenib · midostaurin · gilteritinib · mutated · gene · FLT3

Trametinib is being studied in children with recurrent or refractory juvenile myelomonocytic leukemia.

Sources: Trametinib · recurrent · refractory

Monoclonal antibodies: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.

Sources: Monoclonal antibodies · immune system · proteins · toxins · radioactive

Gemtuzumab ozogamicin is a type of monoclonal antibody that is attached to a chemotherapy drug. It is used in the treatment of AML.

Sources: Gemtuzumab ozogamicin

See Drugs Approved for Leukemia for more information.

Sources: Drugs Approved for Leukemia

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

For patients · Treatment Option Overview / Seven types of standard treatment may be used for childhood AML and other myeloid malignancies.

Other drug therapy

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

Lenalidomide may be used to lessen the need for transfusions in patients who have myelodysplastic syndromes caused by a specific chromosome change.

Sources: Lenalidomide · transfusions · myelodysplastic syndromes · chromosome

Arsenic trioxide and tretinoin are drugs that kill certain types of leukemia cells, stop the leukemia cells from dividing, or help the leukemia cells mature into white blood cells. These drugs are used in the treatment of acute promyelocytic leukemia.

Sources: Arsenic trioxide · tretinoin

See Drugs Approved for Acute Myeloid Leukemia for more information.

Sources: Drugs Approved for Acute Myeloid Leukemia

For patients · Treatment Option Overview / Seven types of standard treatment may be used for childhood AML and other myeloid malignancies.

Watchful waiting

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change. It is sometimes used to treat transient abnormal myelopoiesis (TAM).

Sources: Watchful waiting · monitoring · condition · signs · symptoms

For patients · Treatment Option Overview / Seven types of standard treatment may be used for childhood AML and other myeloid malignancies.

Supportive care

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

Supportive care is given to lessen the problems caused by the disease or its treatment. All patients with leukemia receive supportive care treatments. Supportive care may include the following:

Sources: Supportive care

Transfusion therapy: A way of giving red blood cells or platelets to replace blood cells destroyed by disease or cancer treatment. The blood may be donated from another person or it may have been taken from the patient earlier and stored until needed.

Sources: red blood cells · platelets · donated

Antifungal agents: Drugs, such as Caspofungin or fluconazole, used to prevent or treat infections caused by a fungus (a type of microorganism). This is important in the care of patients with AML.

Sources: Caspofungin · fluconazole · infections · fungus · microorganism

Drug therapy, such as antibiotics.

Sources: Drug therapy · antibiotics

Leukapheresis: A procedure in which a special machine is used to remove white blood cells from the blood. Blood is taken from the patient and put through a blood cell separator where the white blood cells are removed. The rest of the blood is then returned to the patient's bloodstream. Leukapheresis is used to treat patients with very high white blood cell counts.

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for childhood acute myeloid leukemia and other myeloid malignancies may cause side effects.

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Regular follow-up exams are very important. Side effects from cancer treatment that begin after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include the following:

Sources: follow-up · late effects

Physical problems that affect the following:

Heart, lung, or endocrine function.

Sources: lung · endocrine

Bone development.

Fertility (ability to have children).

Sources: Fertility

Energy level.

Changes in mood, feelings, thinking, learning, or memory.

Second cancers (new types of cancer), such as breast cancer.

Sources: Second cancers · breast cancer

Some late effects may be treated or controlled. It is important that parents of children who are treated for AML or other blood diseases talk with their child's doctors about the effects cancer treatment can have on their child. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information).

Sources: blood · Late Effects of Treatment for Childhood Cancer

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Childhood Acute Myeloid Leukemia

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed childhood acute myeloid leukemia (AML) during the induction phase may include the following:

Sources: diagnosed · acute myeloid leukemia · induction

Combination chemotherapy.

Sources: Combination chemotherapy

Central nervous system prophylaxis therapy with intrathecal chemotherapy.

Sources: Central nervous system prophylaxis · therapy · intrathecal chemotherapy

Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).

Sources: Targeted therapy · monoclonal antibody · gemtuzumab ozogamicin

A clinical trial of targeted therapy (sorafenib).

Sources: clinical trial · sorafenib

A clinical trial of chemotherapy and targeted therapy (gilteritinib).

Sources: chemotherapy · gilteritinib

Supportive care.

Sources: Supportive care

Treatment of childhood AML during the remission phase (consolidation/intensification therapy) depends on the subtype of AML and may include the following:

Sources: remission · consolidation · intensification therapy

Combination chemotherapy.

High-dose chemotherapy followed by using blood stem cells from a donor.

Sources: High-dose chemotherapy · Source reference · blood stem cells · donor

Targeted therapy (such as FLT3 inhibitors).

Sources: FLT3

Treatment of refractory childhood AML may include the following:

Sources: refractory

Chemotherapy.

Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).

Radiation therapy to treat a myeloid sarcoma that does not completely respond to chemotherapy.

Sources: Radiation therapy · myeloid sarcoma

Treatment of recurrent childhood AML may include the following:

Sources: recurrent

Combination chemotherapy.

Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).

Radiation therapy to treat locally recurring myeloid sarcoma.

A clinical trial of targeted therapy (midostaurin, sorafenib, or gilteritinib).

Sources: midostaurin

Combination chemotherapy and stem cell transplant, for patients who have had a second complete remission.

A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.

For patients

Treatment of Transient Abnormal Myelopoiesis or Children with Down Syndrome and AML

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Transient abnormal myelopoiesis (TAM) usually goes away on its own. For newly diagnosed TAM that does not go away on its own or causes other health problems, treatment may include the following:

Sources: Transient abnormal myelopoiesis · diagnosed

Supportive care, including transfusion therapy or leukapheresis.

Sources: Supportive care · transfusion · leukapheresis

Chemotherapy.

Sources: Chemotherapy

Treatment of newly diagnosed acute myeloid leukemia (AML) in children aged 4 years or younger who have Down syndrome may include the following:

Sources: acute myeloid leukemia · Down syndrome

Combination chemotherapy plus central nervous system prophylaxis therapy with intrathecal chemotherapy.

Sources: Combination chemotherapy · central nervous system prophylaxis · intrathecal chemotherapy

A clinical trial of a new chemotherapy regimen that depends on how the child responds to initial chemotherapy.

Sources: clinical trial · regimen · responds

Treatment of newly diagnosed AML in children older than 4 years who have Down syndrome may be the same as treatment for children without Down syndrome.

For patients

Treatment of Childhood Acute Promyelocytic Leukemia

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed childhood acute promyelocytic leukemia (APL) may include the following:

Sources: diagnosed · acute promyelocytic leukemia

Tretinoin with arsenic trioxide.

Sources: Tretinoin · arsenic trioxide

Tretinoin plus chemotherapy with or without arsenic trioxide.

Sources: chemotherapy

Supportive care.

Sources: Supportive care

Treatment of childhood APL during the remission phase (consolidation/intensification therapy) may include the following:

Sources: remission · consolidation · intensification therapy

Tretinoin with arsenic trioxide.

Tretinoin plus chemotherapy with or without arsenic trioxide.

Treatment of childhood APL during the remission phase (maintenance therapy) may include the following:

Sources: maintenance therapy

Tretinoin with combination chemotherapy.

Sources: combination chemotherapy

Treatment of recurrent childhood APL may include the following:

Sources: recurrent

Arsenic trioxide therapy with or without tretinoin.

Targeted therapy with a monoclonal antibody (gemtuzumab ozogamicin).

Sources: Targeted therapy · monoclonal antibody · gemtuzumab ozogamicin

Stem cell transplant using blood stem cells from the patient or a donor.

Sources: Stem cell transplant · blood stem cells · donor

For patients

Treatment of Juvenile Myelomonocytic Leukemia

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed juvenile myelomonocytic leukemia (JMML) may include the following:

Sources: diagnosed · juvenile myelomonocytic leukemia

Combination chemotherapy followed by stem cell transplant.

Sources: Combination chemotherapy · stem cell transplant

Treatment of refractory or recurrent childhood JMML may include the following:

Sources: refractory · recurrent

A second stem cell transplant, for patients whose disease came back after the first stem cell transplant.

A clinical trial of targeted therapy with a tyrosine kinase inhibitor (trametinib).

Sources: clinical trial · targeted therapy · tyrosine kinase inhibitor · trametinib

For patients

Treatment of Childhood Chronic Myelogenous Leukemia

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed chronic myelogenous leukemia (CML) may include the following:

Sources: diagnosed · chronic myelogenous leukemia

Targeted therapy with a tyrosine kinase inhibitor (imatinib, dasatinib, or nilotinib).

Sources: Targeted therapy · tyrosine kinase inhibitor · imatinib · dasatinib · nilotinib

A clinical trial to study the rate of CML recurrence after stopping tyrosine kinase inhibitor therapy, and the ability to achieve remission again if CML recurs in children with CML who are in remission for at least 2 years after receiving treatment with the same tyrosine kinase inhibitor for at least 3 years.

Sources: clinical trial · recurrence · remission

Treatment of refractory or recurrent childhood CML may include the following:

Sources: refractory · recurrent

Targeted therapy with a tyrosine kinase inhibitor (dasatinib or nilotinib).

Stem cell transplant using blood stem cells from a donor.

Sources: Stem cell transplant · blood stem cells · donor

For patients

Treatment of Childhood Myelodysplastic Syndromes

Source: Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: June 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed childhood myelodysplastic syndromes (MDS) may include the following:

Sources: diagnosed · myelodysplastic syndromes

Stem cell transplant using blood stem cells from a donor.

Sources: Stem cell transplant · blood stem cells · donor

Supportive care, including transfusion therapy and antibiotics.

Sources: Supportive care · transfusion · therapy · antibiotics

Steroid therapy.

Sources: Steroid therapy

Lenalidomide therapy, for patients with certain gene changes.

Sources: Lenalidomide · therapy · gene

If the MDS becomes acute myeloid leukemia (AML), treatment will be the same as treatment for newly diagnosed AML.

Sources: acute myeloid leukemia · diagnosed

Studies

Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia

NCT00002658 · UNKNOWN · phase3

Leukemia, Neutropenia

ClinicalTrials.gov record

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002798 · COMPLETED · phase3

Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b),...

ClinicalTrials.gov record

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

NCT00028899 · COMPLETED · phase1

Leukemia, Myelodysplastic Syndromes

ClinicalTrials.gov record

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

NCT00070174 · COMPLETED · phase2

Leukemia

ClinicalTrials.gov record

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

NCT00111345 · UNKNOWN · phase2, phase3

Myeloid Leukemia

ClinicalTrials.gov record

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

NCT00136084 · COMPLETED · phase3

Leukemia, Myelocytic, Acute

ClinicalTrials.gov record

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

NCT00186966 · COMPLETED · phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

NCT00306202 · COMPLETED · phase1

Leukemia

ClinicalTrials.gov record

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00372593 · COMPLETED · phase3

Leukemia

ClinicalTrials.gov record

Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

NCT00372619 · COMPLETED · phase1, phase2

Leukemia

ClinicalTrials.gov record

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

NCT00476541 · COMPLETED · phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

NCT00703820 · COMPLETED · phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

NCT00866281 · TERMINATED · phase1, phase2

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia

ClinicalTrials.gov record

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

NCT00927498 · COMPLETED · phase3

Acute Myeloid Leukemia

ClinicalTrials.gov record

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

NCT01088984 · COMPLETED · phase1, phase2

Leukemia

ClinicalTrials.gov record

Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia

NCT01307579 · COMPLETED · phase3

Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With...

ClinicalTrials.gov record

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation

NCT01371656 · COMPLETED · phase3

Acute Leukemias of Ambiguous Lineage, Bacterial Infection, Diarrhea, Fungal Infection, Musculoskeletal Complications, Neutropenia, Recurrent Childhood Acute Lymphoblastic...

ClinicalTrials.gov record

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01371981 · COMPLETED · phase3

Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma

ClinicalTrials.gov record

Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years

NCT01828489 · UNKNOWN · phase3

Pediatric Acute Myeloblastic Leukemia

ClinicalTrials.gov record

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

NCT02421939 · COMPLETED · phase3

Leukemia, Acute Myeloid (AML)

ClinicalTrials.gov record

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02642965 · COMPLETED · phase1, phase2

Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia

ClinicalTrials.gov record

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

NCT02724163 · ACTIVE NOT RECRUITING · phase3

Acute Myeloid Leukaemia

ClinicalTrials.gov record

Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

NCT03194932 · COMPLETED · phase1

Acute Myeloid Leukemia

ClinicalTrials.gov record

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

NCT03591510 · ACTIVE NOT RECRUITING · phase2

FLT3-mutated Acute Myeloid Leukemia

ClinicalTrials.gov record

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT03860844 · TERMINATED · phase2

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia

ClinicalTrials.gov record

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00119366 · TERMINATED · phase2

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid...

ClinicalTrials.gov record

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

NCT00322101 · COMPLETED · phase3

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid...

ClinicalTrials.gov record

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

NCT00416884 · TERMINATED · phase2

Leukemia

ClinicalTrials.gov record

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

NCT00445744 · COMPLETED · na

Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia...

ClinicalTrials.gov record

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

NCT00540995 · TERMINATED · phase1, phase2

Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia...

ClinicalTrials.gov record

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

NCT00553202 · COMPLETED · phase2

Leukemia

ClinicalTrials.gov record

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

NCT01036009 · COMPLETED · phase2

Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile...

ClinicalTrials.gov record

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

NCT01083706 · COMPLETED · phase2

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid...

ClinicalTrials.gov record

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

NCT01640301 · TERMINATED · phase1, phase2

Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Donor,...

ClinicalTrials.gov record

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

NCT01760655 · COMPLETED · phase2

Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid...

ClinicalTrials.gov record

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

NCT02120157 · COMPLETED · phase2

Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow

ClinicalTrials.gov record

Disease and treatment settings

Childhood Acute Myeloid Leukemia

Disease and treatment setting

Acute Myeloid Leukemia in children and adolescents

Infant Acute Biphenotypic Leukemia

Disease and treatment setting

Infant Acute Biphenotypic Leukemia

Infant Acute Undifferentiated Leukemia

Disease and treatment setting

Infant Acute Undifferentiated Leukemia

recurrent Childhood Acute Myeloid Leukemia

Disease and treatment setting

Treatment of Recurrent or Refractory Childhood AML

refractory Childhood Acute Myeloid Leukemia

Disease and treatment setting

Refractory Childhood AML (Induction Failure)